Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids

Biochem Pharmacol. 2018 Dec:158:261-273. doi: 10.1016/j.bcp.2018.10.031. Epub 2018 Oct 31.

Abstract

Epithelial mesenchymal transition (EMT) is a biological process that plays a critical role in cancer progression. Blocking the process of EMT can be an essential strategy in the development of anticancer drugs. In this paper, we briefly introduce recent research trends and issues of EMT, focusing on the relationship of EMT with the entire cycle of inflammation (from initiation to resolution of inflammation). Recent findings on the relationship between EMT and immune evasion are discussed. We will also explore the importance of controlling inflammation by anti-inflammatory compounds and specialized pro-resolving lipids to inhibit EMT process in cancer.

Keywords: Anti-inflammatory compounds; Epithelial mesenchymal transition; Immune evasion; Inflammation; Pro-resolving specialized lipids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Docosahexaenoic Acids / pharmacology*
  • Docosahexaenoic Acids / therapeutic use
  • Epithelial-Mesenchymal Transition / drug effects
  • Epithelial-Mesenchymal Transition / physiology*
  • Humans
  • Lipids
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / physiology*

Substances

  • Anti-Inflammatory Agents
  • Lipids
  • resolvin D1
  • Docosahexaenoic Acids